查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612197

抗疟疾药市场：按药物类别、按药物类型、按给药途径、按疟疾类型、按分销渠道、按最终用户 - 2025-2030 年全球预测

Antimalarial Drugs Market by Drug Class (Antifolate compounds, Artemisinin compounds, Aryl aminoalcohol compounds), Drug Type (Branded, Generic), Route of Administration, Malaria Type, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗疟疾药市值为16.7亿美元，预计2024年将达到17.6亿美元，复合年增长率为5.88%，预计2030年将达25亿美元。

抗疟疾药的范围是用于预防和治疗疟疾的开发、分销和应用，疟疾是一种由寄生虫引起的疾病，主要透过受感染的蚊子叮咬传播。疟疾的持续流行证明了对这些药物的需求，特别是在热带和亚热带地区，疟疾对这些地区的健康构成了重大挑战。抗疟疾药不仅可用于疾病流行地区，还可作为前往这些地区的人们的旅行药物。最终的使用范围将包括公共卫生活动、医院、诊所和药房的店面销售，以满足流行地区居民和游客的需求。

主要市场统计
基准年[2023] 16.7亿美元
预计年份 [2024] 17.6亿美元
预测年份 [2030] 25亿美元
复合年增长率（%） 5.88%

根据市场洞察，抗疟疾药的需求受到全球疟疾流行、全球卫生措施以及持续的抗药性研究工作等因素的影响。在政府措施以及製药公司与卫生当局之间的合作伙伴关係的推动下，对开发下一代治疗方法（包括疫苗和新药物配方）的投资也在增加。将人工智慧等新技术融入药物发现、扩大农村地区的使用范围以及开发儿童友善配方等方面存在潜在机会。然而，疟疾原虫抗药性菌株的出现、药物开发高成本以及监管障碍等挑战带来了限制。这些障碍可能会减缓市场成长并需要持续的研究工作。

创新可能会在对抗抗药性细菌的联合治疗、开发快速诊断测试以指南个人化治疗以及利用生物技术开发疫苗等领域取得进展。儘管市场竞争依然激烈，但新参与企业仍有空间愿意投资研发和合作。了解当地市场动态并使您的产品线多样化以满足当地需求可以提高您的市场占有率。总之，要抓住抗疟疾药市场的成长机会，必须对抗药性趋势保持警惕，利用技术进步并应对获取挑战。

市场动态：揭示快速发展的抗疟疾药市场的关键市场洞察

供需的动态交互作用正在改变抗疟疾药市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球疟疾发病率上升（特别是在热带和亚热带地区）
    • 世界卫生组织加大对消除疟疾计画的支持
  • 市场限制因素
    • 抗药性疟疾菌株的出现
  • 市场机会
    • 政府与製药公司之间的合作关係旨在扩大抗疟疾药的传播
    • 疟疾治疗的发展和诊断测试的研发
  • 市场问题
    • 剂量不正确、严格遵守规定、药品品质差等问题

波特五力：驾驭抗疟疾药市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗疟疾药市场的外部影响

外部宏观环境因素在塑造抗疟疾药市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解抗疟疾药市场的竞争格局

抗疟疾药市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：抗疟疾药市场供应商绩效评估

FPNV定位矩阵是评估抗疟疾药市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製抗疟疾药市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，抗疟疾药市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 疟疾的发生率在全世界范围内不断增加，特别是在热带和亚热带地区。
      • 世界卫生组织加大对消除疟疾计画的支持
    • 抑制因素
      • 抗药性疟疾菌株的出现
    • 机会
      • 政府与药厂合作促进抗疟疾药普及
      • 疟疾药物开发与诊断测试的研究与开发
    • 任务
      • 与剂量错误、严格遵守和药品品质不佳有关的问题
  • 市场区隔分析
    • 药物类别：青蒿素化合物的功效扩大了用途
    • 疟疾类型：疟疾原虫盛行率增加
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章抗疟疾药市场：依药物类别

  • 介绍
  • 抗叶酸化合物
  • 青蒿素化合物
  • 胺基醇化合物
  • 内过氧化物
  • 喹啉甲醇
  • 四环霉素

第七章抗疟疾药市场：按药物类型

  • 介绍
  • 品牌
  • 非专利的

抗疟疾药市场：依给药途径

  • 介绍
  • 静脉
  • 口服

第九章抗疟疾药市场：依疟疾类型

  • 介绍
  • Plasmodium Falciparum
  • Plasmodium Knowlesi
  • Plasmodium Malariae
  • Plasmodium Ovale
  • Plasmodium Vivax

第十章抗疟疾药市场：依通路划分

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第十一章抗疟疾药市场：依最终用户分类

  • 介绍
  • 医院
  • 专科诊所

第十二章美洲抗疟疾药市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太抗疟疾药市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章欧洲、中东和非洲抗疟疾药市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 肯亚製药公司成为非洲第一家获得世界卫生组织核准用于疟疾治疗的製药公司
    • 復星医药与国际金融公司合作改善非洲优质药品的获取
    • 復星医药研发青蒿素类创新抗疟疾药
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Alkem Laboratories
  • Alliance Pharma
  • Alvizia Health Care
  • Bayer AG
  • Cipla Inc.
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Ipca Laboratories Ltd.
  • Lincoln Pharmaceuticals
  • Lupin Limited
  • Merck KGaA
  • Mylan
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Group
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Group
  • Zydus Lifesciences Ltd.
Product Code: MRR-F97DD5A7DAEF

The Antimalarial Drugs Market was valued at USD 1.67 billion in 2023, expected to reach USD 1.76 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 2.50 billion by 2030.

The scope of antimalarial drugs encompasses their development, distribution, and application primarily for the prevention and treatment of malaria, a disease caused by parasites transmitted through infected mosquito bites. The necessity for these drugs is underscored by malaria's persistent prevalence, particularly in tropical and subtropical regions, where it poses significant health challenges. Antimalarial drugs find application not only in disease-endemic regions but also in travel medicine for individuals visiting such areas. Ultimately, the end-use scope includes public health initiatives, hospitals, clinics, and over-the-counter availability in pharmacies, catering to both the endemic population and travelers.

KEY MARKET STATISTICS
Base Year [2023] USD 1.67 billion
Estimated Year [2024] USD 1.76 billion
Forecast Year [2030] USD 2.50 billion
CAGR (%) 5.88%

Market insights reveal that the demand for antimalarial drugs is influenced by factors such as the global incidence rate of malaria, international health policies, and ongoing research efforts into drug resistance. There's also an increased investment in developing next-generation therapies, including vaccines and novel drug formulations, driven by government initiatives and collaborations between pharmaceutical companies and health organizations. Potential opportunities lie in the integration of new technologies such as AI in drug discovery, expanding access to rural areas, and developing pediatric-friendly formulations. However, limitations arise from challenges such as the emergence of drug-resistant strains of malaria parasites, high costs of drug development, and regulatory hurdles. These impediments may slow market growth and require sustained research efforts.

Innovation can thrive in areas like combination therapies to tackle resistance, development of rapid diagnostic tests that can guide personalized treatment, and leveraging biotechnology for vaccine development. The market remains competitive but offers room for new entrants willing to invest in R&D and collaborations. Understanding regional market dynamics and diversifying product lines to align with specific local needs can enhance market presence. In summary, maintaining vigilance on resistance trends, capitalizing on technological advancements, and addressing access challenges are crucial for seizing growth opportunities in the antimalarial drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antimalarial Drugs Market

The Antimalarial Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence rates of malaria globally, particularly in tropical and subtropical regions
    • Increasing support from global health organizations for malaria eradication programs
  • Market Restraints
    • Emergence of drug-resistant malaria strains
  • Market Opportunities
    • Collaborations between governments and pharmaceutical companies for increasing penetration of anti-malaria drugs
    • Research and development in drug development and diagnostic tests for malaria
  • Market Challenges
    • Issues related to incorrect dosing, strict compliance, and poor drug quality

Porter's Five Forces: A Strategic Tool for Navigating the Antimalarial Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antimalarial Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antimalarial Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antimalarial Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antimalarial Drugs Market

A detailed market share analysis in the Antimalarial Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antimalarial Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antimalarial Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antimalarial Drugs Market

A strategic analysis of the Antimalarial Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antimalarial Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories, Alliance Pharma, Alvizia Health Care, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals, Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Lincoln Pharmaceuticals, Lupin Limited, Merck KGaA, Mylan, Novartis AG, Pfizer Inc., Sanofi Group, Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Teva Pharmaceuticals Industries Ltd., Zydus Group, and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Antimalarial Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Antifolate compounds, Artemisinin compounds, Aryl aminoalcohol compounds, Endoperoxides, Quinoline Methanols, and Tetracyclines.
  • Based on Drug Type, market is studied across Branded and Generic.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on Malaria Type, market is studied across Plasmodium Falciparum, Plasmodium Knowlesi, Plasmodium Malariae, Plasmodium Ovale, and Plasmodium Vivax.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End User, market is studied across Hospitals and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence rates of malaria globally, particularly in tropical and subtropical regions
      • 5.1.1.2. Increasing support from global health organizations for malaria eradication programs
    • 5.1.2. Restraints
      • 5.1.2.1. Emergence of drug-resistant malaria strains
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborations between governments and pharmaceutical companies for increasing penetration of anti-malaria drugs
      • 5.1.3.2. Research and development in drug development and diagnostic tests for malaria
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to incorrect dosing, strict compliance, and poor drug quality
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Widening use of artemisinin compounds owing to its effective results
    • 5.2.2. Malaria Type: Increasing prevalence of plasmodium falciparum
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antimalarial Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Antifolate compounds
  • 6.3. Artemisinin compounds
  • 6.4. Aryl aminoalcohol compounds
  • 6.5. Endoperoxides
  • 6.6. Quinoline Methanols
  • 6.7. Tetracyclines

7. Antimalarial Drugs Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Branded
  • 7.3. Generic

8. Antimalarial Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. Antimalarial Drugs Market, by Malaria Type

  • 9.1. Introduction
  • 9.2. Plasmodium Falciparum
  • 9.3. Plasmodium Knowlesi
  • 9.4. Plasmodium Malariae
  • 9.5. Plasmodium Ovale
  • 9.6. Plasmodium Vivax

10. Antimalarial Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Antimalarial Drugs Market, by End User

  • 11.1. Introduction
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Americas Antimalarial Drugs Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Antimalarial Drugs Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Antimalarial Drugs Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Kenya Manufacturer Is First In Africa to Get WHO Approval For Malaria Drug
    • 15.3.2. Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa
    • 15.3.3. Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alkem Laboratories
  • 3. Alliance Pharma
  • 4. Alvizia Health Care
  • 5. Bayer AG
  • 6. Cipla Inc.
  • 7. Dr. Reddy's Laboratories
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. GlaxoSmithKline plc
  • 10. Glenmark Pharmaceuticals
  • 11. Hikma Pharmaceuticals PLC
  • 12. Ipca Laboratories Ltd.
  • 13. Lincoln Pharmaceuticals
  • 14. Lupin Limited
  • 15. Merck KGaA
  • 16. Mylan
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Sanofi Group
  • 20. Strides Pharma Science Limited
  • 21. Sun Pharmaceutical Industries Ltd.
  • 22. Takeda Pharmaceutical Company
  • 23. Teva Pharmaceuticals Industries Ltd.
  • 24. Zydus Group
  • 25. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIMALARIAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIMALARIAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIMALARIAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIMALARIAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ANTIFOLATE COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARYL AMINOALCOHOL COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ENDOPEROXIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUINOLINE METHANOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM FALCIPARUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM KNOWLESI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM MALARIAE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM OVALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM VIVAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 283. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023